Recently Featured

Sling ropes in $123m for oral thyroid eye disease drug

October 5, 2026
Sling has secured $123 million in funding to accelerate the development of its oral thyroid eye disease drug, positioning itself as a potential competitor to Amgen’s Tepezza, the current market leader. This significant investment underscores the growing interest in innovative treatments for thyroid eye disease, a condition that affects many patients and has seen limited…

AZ, Daiichi’s Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

October 5, 2026
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu has received a positive cost-effectiveness assessment from the National Institute for Health and Care Excellence (NICE) for use in treating HER2-low advanced breast cancer. This decision comes after a previous rejection in 2024, marking a significant turnaround for the drug’s market access in England and Wales. The NICE…

Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

October 5, 2026
The Danish drugmaker Novo Nordisk has announced its collaboration with Anthropic to leverage the AI model Claude Science, aiming to enhance its drug development processes. This strategic partnership underscores Novo’s ambition to position itself as the leading AI-driven healthcare company globally. As the pharmaceutical industry increasingly embraces artificial intelligence, Novo’s initiative reflects a broader trend…

Stanford Scientists Create Neuro-Chimeric Mice with Human Brain Organoids

October 5, 2026
Researchers at Stanford University have developed a groundbreaking method to grow human cerebral organoids within genetically modified mice that have had significant portions of their own brains removed. This innovative approach enhances the study of brain development and disease by allowing scientists to observe human brain cells in a living organism, a significant advancement in…

Ongoing Cases